<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031499</url>
  </required_header>
  <id_info>
    <org_study_id>99-005</org_study_id>
    <nct_id>NCT00031499</nct_id>
  </id_info>
  <brief_title>Azithromycin/Bicillin Syphilis</brief_title>
  <official_title>A Phase III Equivalence Trial of Azithromycin vs. Benzathine Penicillin for the Treatment of Early Syphilis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if azithromycin, a drug approved for treatment of
      other infections, is as effective for syphilis (a sexually transmitted disease) as the
      standard treatment. Approximately 600 healthy adults, who are HIV-negative, ages 18 to 55
      years of age, with primary, secondary or early latent syphilis, will participate in this
      research study. Volunteers will be enrolled in 5 U.S. cities and in Madagascar. Participants
      will be chosen randomly (by chance) to receive 1 of 2 study drugs: benzathine penicillin
      given (2 shots in the buttocks) or 4 tablets of azithromycin. Subjects who report a history
      of a penicillin allergy will be given either 2.0 g of oral azithromycin or 100 mg doxycycline
      taken orally, twice a day for 14 days. Over 2 years, 10 visits will be required. Procedures
      will include blood samples, physical exams, and swabs of sores.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Syphilis is a disease with a worldwide distribution. It causes genital ulceration, thereby
      amplifying risk for HIV acquisition and transmission and it may cause congenital infection,
      spontaneous abortion, and stillbirth if untreated in pregnant women. About one third of all
      cases, if untreated, result in late sequelae which include neurosyphilis, gumma formation and
      cardiovascular involvement. This study will be a multi-center, randomized, open-label trial
      to evaluate the efficacy of azithromycin in treating primary, secondary and early latent
      syphilis in HIV (Human Immunodeficiency Virus) uninfected volunteers. Up through version 6.0
      of this protocol volunteers were only followed for 12 months. The protocol was amended
      starting with version 7.0 to include follow-up visits at month 18 and 24 in order to capture
      possible &quot;late failures.&quot; Each subject will be randomized into a treatment group. If the
      subject does not have a self-reported history of penicillin allergy, the subject will be
      randomized to receive either a single 2.0 gram dose of azithromycin administered orally, or
      2.4 million units of benzathine penicillin G administered intramuscularly once. Eligible
      patients who report a history of penicillin allergy will be randomized (using a separate
      randomization schedule) to receive either a single dose of azithromycin or doxycycline, 100
      milligrams, taken orally, twice a day for 14 days. Block randomization will be used within
      each clinical center with subjects allocated in equal numbers to either standard therapy or
      azithromycin. Participants found to be ineligible for study participation after they have
      been randomized and treated, will be treated again with benzathine penicillin G (or
      doxycycline if they are allergic to penicillin) and will continue follow-up for safety
      evaluation. The treatment assignments will not be blinded. No attempt will be made to recruit
      a sufficient sample size among penicillin allergic subjects to attain the desired power for
      the primary outcome. Therefore these results will be seen as preliminary to a possible future
      trial and as confirmatory to the primary comparison. Although the study endpoint will be
      determined at 6 months, all participants, will have follow-up visits for 2 full years. At the
      end of the 6 month evaluation period, all participants will have been classified in one of
      the following groups: cure; clinical response/serological nonresponse; or failure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure of syphilis defined as a negative reactive serologic test for syphilis (RPR) titer or greater than or equal to a 4-fold (2 dilution) decrease in RPR titer at 6 months following treatment and resolution of all signs and symptoms of syphilis.</measure>
    <time_frame>Month 6.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cure rates at 9, 12 and 24 months post treatment and the rate of relapse or reinfection defined as cure followed by recurrent clinical manifestations or a 2-dilution increase in RPR titer over previous lowest result.</measure>
    <time_frame>Months 9, 12, and 24.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">593</enrollment>
  <condition>Syphilis</condition>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin 2.0 gram single oral dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benzathine Penicillin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benzathine penicillin 2.4 million units administered intramuscularly. Doxycycline will be administered if the patient is allergic to Benzathine Penicillin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Single 2 gram oral dose (4 tablets) at Day 1.</description>
    <arm_group_label>Azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzathine Penicillin</intervention_name>
    <description>Supplied in pre-filled syringes containing 1.2 million units of benzathine penicillin; 2.4 million units administered intramuscularly at Day 1, in one or both buttocks.</description>
    <arm_group_label>Benzathine Penicillin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Baseline visit, 28 capsules dispensed, for a dose of 100 mg twice a day (BID).</description>
    <arm_group_label>Benzathine Penicillin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is 18 to 55 years of age.

          -  The subject has signed written informed consent.

          -  The subject has untreated primary [darkfield or Treponema (T.) pallidum by a rapid,
             direct, fluorescent antibody darkfield (DFA-TP)] positive genital ulcers, secondary
             (based on classical palmar/plantar rash, condylomata lata, mucous patches, etc. or
             darkfield or DFA-TP positive lesions), or early latent syphilis (e.g., current
             reactive serologic tests for syphilis (STS), and a documented non-reactive STS or
             documented sexual exposure to a known early latent, primary or secondary syphilis
             patient in last 12 months; identification of this sexual contact must occur within 60
             days of admission into the study).

          -  The subject has laboratory evidence of syphilis, i.e., reactive serologic test for
             syphilis (RPR).

          -  The subject is not pregnant, as documented by a negative urine or serum pregnancy
             test, or lactating.

          -  The subject is willing to have an HIV test, and, participate in HIV counseling and
             return to the clinic for follow-up treatment.

        Exclusion Criteria:

          -  The subject does not have reactive serologic tests for syphilis.

          -  The subject has latent syphilis of unknown duration, late latent syphilis or evidence
             of neurosyphilis.

          -  The subject has a known or suspected allergy to macrolide or azalide antibiotics.

          -  The subject has a known or suspected sexually transmitted disease (STD), other than
             syphilis requiring treatment with a drug, other than azithromycin, active against T.
             pallidum.

          -  The subject has used antibiotics active against T. pallidum in the preceding 30 days.
             (Note: the use of antimicrobials known to NOT be effective against T. pallidum such as
             quinolones, sulfonamides, trimethoprim, metronidazole and spectinomycin will be
             allowed).

          -  The subject is known to be HIV positive prior to enrollment.

          -  The subject has suspected or known ongoing drug use that might interfere with study
             participation and follow-up treatment.

          -  The subject has a history of cardiovascular disease, known immunosuppression, or known
             AIDS, which might compromise response to therapy.

          -  The subject is judged by the investigators to be unlikely to reliably participate in
             the study follow-up.

          -  The subject has used any investigational drugs in the past 30 days.

          -  The subject has any other condition that may impair drug absorption (malabsorption
             syndrome or active peptic ulcer disease).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama Hospital - Infectious Diseases</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center - Infectious Diseases</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112-2865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital - Medicine - Infectious Diseases</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-0005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina School of Medicine - Center for Infectious Diseases</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham County Health Department</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701-3720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire National de Reference sur le VIH/SIDA (LNR)</name>
      <address>
        <city>Analamanga</city>
        <state>Antananarivo</state>
        <zip>101</zip>
        <country>Madagascar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaly Kely</name>
      <address>
        <city>Tamatave</city>
        <state>Antsiranana</state>
        <country>Madagascar</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaly Mahabibo</name>
      <address>
        <city>Mahajanga Majunga</city>
        <state>Mahajanga</state>
        <zip>401</zip>
        <country>Madagascar</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Madagascar</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Se√±a AC, Wolff M, Martin DH, Behets F, Van Damme K, Leone P, Langley C, McNeil L, Hook EW. Predictors of serological cure and Serofast State after treatment in HIV-negative persons with early syphilis. Clin Infect Dis. 2011 Dec;53(11):1092-9. doi: 10.1093/cid/cir671. Epub 2011 Oct 12.</citation>
    <PMID>21998287</PMID>
  </results_reference>
  <results_reference>
    <citation>Hook EW 3rd, Behets F, Van Damme K, Ravelomanana N, Leone P, Sena AC, Martin D, Langley C, McNeil L, Wolff M. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. J Infect Dis. 2010 Jun 1;201(11):1729-35. doi: 10.1086/652239.</citation>
    <PMID>20402591</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2002</study_first_submitted>
  <study_first_submitted_qc>March 6, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2002</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Azithromycin, Syphilis, Penicillin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Penicillins</mesh_term>
    <mesh_term>Penicillin G Benzathine</mesh_term>
    <mesh_term>Penicillin G</mesh_term>
    <mesh_term>Penicillin G Procaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

